694 related articles for article (PubMed ID: 27918650)
1. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
[TBL] [Abstract][Full Text] [Related]
2. [Clinical value of p16
Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
[No Abstract] [Full Text] [Related]
3. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+).
Tay TKY; Lim KL; Hilmy MH; Thike AA; Goh ST; Song LH; Hwang JSG; Mantoo S
Malays J Pathol; 2017 Dec; 39(3):257-265. PubMed ID: 29279588
[TBL] [Abstract][Full Text] [Related]
4. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
5. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
[TBL] [Abstract][Full Text] [Related]
6. Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion.
Koo YJ; Hahn HS; Lee IH; Lim KT; Lee KH; Kim HS; Kim TJ; Chun YK; Kim HS; Hong SR
Virchows Arch; 2013 Nov; 463(5):689-96. PubMed ID: 24081504
[TBL] [Abstract][Full Text] [Related]
7. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.
Ebisch RM; van der Horst J; Hermsen M; Rijstenberg LL; Vedder JE; Bulten J; Bosgraaf RP; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Massuger LF; Melchers WJ; Bekkers RL; Siebers AG
Mod Pathol; 2017 Jul; 30(7):1021-1031. PubMed ID: 28304400
[TBL] [Abstract][Full Text] [Related]
9. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
Uijterwaal MH; Witte BI; Van Kemenade FJ; Rijkaart D; Ridder R; Berkhof J; Balfoort-van der Meij GA; Bleeker MC; Snijders PJ; Meijer CJ
Br J Cancer; 2014 Mar; 110(6):1579-86. PubMed ID: 24518601
[TBL] [Abstract][Full Text] [Related]
10. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R;
J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620
[TBL] [Abstract][Full Text] [Related]
11. Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.
Polman NJ; Uijterwaal MH; Witte BI; Berkhof J; van Kemenade FJ; Spruijt JW; van Baal WM; Graziosi PG; van Dijken DK; Verheijen RH; Helmerhorst TJ; Steenbergen RD; Heideman DA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2017 Jan; 140(2):423-430. PubMed ID: 27677098
[TBL] [Abstract][Full Text] [Related]
12. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
13. Good performance of p16/Ki-67 dual-stain cytology for detection and post-treatment surveillance of high-grade CIN/VAIN in a prospective, cross-sectional study.
Liu W; Gong J; Xu H; Zhang D; Xia N; Li H; Song K; Lv T; Chen Y; Diao Y; Jao J; Dai S; Zhao P; Yao Q
Diagn Cytopathol; 2020 Jul; 48(7):635-644. PubMed ID: 32275355
[TBL] [Abstract][Full Text] [Related]
14. p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women with abnormal cytology under 30 years old.
Pirtea L; Secosan C; Margan M; Moleriu L; Balint O; Grigoras D; Sas I; Horhat F; Jianu A; Ilina R
Bosn J Basic Med Sci; 2019 Nov; 19(4):336-341. PubMed ID: 29924960
[TBL] [Abstract][Full Text] [Related]
15. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
16. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.
Petry KU; Schmidt D; Scherbring S; Luyten A; Reinecke-Lüthge A; Bergeron C; Kommoss F; Löning T; Ordi J; Regauer S; Ridder R
Gynecol Oncol; 2011 Jun; 121(3):505-9. PubMed ID: 21420158
[TBL] [Abstract][Full Text] [Related]
17. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
Cuzick J; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Del Mistro A; Frayle H; Girlando S; Sani C; Confortini M; Zorzi M; Giorgi-Rossi P; Rizzolo R; Ronco G;
Int J Cancer; 2020 Oct; 147(7):1864-1873. PubMed ID: 32170961
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
Yu LL; Chen W; Lei XQ; Qin Y; Wu ZN; Pan QJ; Zhang X; Chang BF; Zhang SK; Guo HQ; Qiao YL
Oncotarget; 2016 Apr; 7(16):21181-9. PubMed ID: 27029033
[TBL] [Abstract][Full Text] [Related]
19. Combining HPV DNA load with p16/Ki-67 staining to detect cervical precancerous lesions and predict the progression of CIN1-2 lesions.
Li Y; Liu J; Gong L; Sun X; Long W
Virol J; 2019 Oct; 16(1):117. PubMed ID: 31619262
[TBL] [Abstract][Full Text] [Related]
20. Interlaboratory concordance of p16/Ki-67 dual-staining interpretation in HPV-positive women in a screening population.
Benevolo M; Mancuso P; Allia E; Gustinucci D; Bulletti S; Cesarini E; Carozzi FM; Confortini M; Bisanzi S; Carlinfante G; Rubino T; Rollo F; Marchi N; Farruggio A; Pusiol T; Venturelli F; Giorgi Rossi P;
Cancer Cytopathol; 2020 May; 128(5):323-332. PubMed ID: 32168431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
